Serum Patents (Class 435/392)
-
Patent number: 11723934Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.Type: GrantFiled: February 8, 2019Date of Patent: August 15, 2023Assignee: Keio UniversityInventors: Kenya Honda, Takeshi Tanoue, Yutaka Kawakami, Koji Atarashi, Satoru Morita, Ashwin Nicholas Skelly
-
Patent number: 9700582Abstract: The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.Type: GrantFiled: September 10, 2008Date of Patent: July 11, 2017Assignee: Sapporo Medical UniversityInventors: Osamu Honmou, Kiyohiro Houkin
-
Patent number: 9644182Abstract: Described is a method of expanding human progenitor cells by suspension culturing under non-static conditions. The culturing method provides a three-dimensional space for the rapid expansion of desirable progenitors. By this method, a new compartment of multipotential progenitor cells has been identified, which give rise under differentiation conditions to progeny including osteoblasts, chondrocytes, myoblasts, adipocytes, and other non-hematopoietic cell types. Their use in cell and tissue-based engineering is described.Type: GrantFiled: July 26, 2007Date of Patent: May 9, 2017Inventors: Dolores Baksh, John E. Davies, Peter Zandstra
-
Patent number: 9512403Abstract: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.Type: GrantFiled: August 27, 2013Date of Patent: December 6, 2016Assignee: Histogen, Inc.Inventors: Gail K. Naughton, Frank Ziegler, Mark Baumgartner, Kyle Nickey
-
Patent number: 9372132Abstract: A blood component sampling system and method are disclosed. The system is pre-connected and includes a collected blood component container and a reservoir having substantially fixed volume and at least one volumetric indicator indicating a selected volume and a sample container docking station configured to cooperate with a sample collection container. The system and method provide ease of sampling with reduced risk of contamination.Type: GrantFiled: March 5, 2013Date of Patent: June 21, 2016Assignee: Fenwal, Inc.Inventors: Tat Mui, Randy Murphey, Daniel Lynn, Richard L. West, Hugo Ramon, Shawn Davis
-
Patent number: 8927276Abstract: The present invention relates to a simplified process, which is shorter in time, for propagation of proliferating cells, such as e.g. progenitor or stem cells, by means of a biphasic culturing system having a differentiation supporting component and a proliferation supporting component, and to the use of the stem cell cultures obtained in this way for cell therapy purposes. The present invention invention describes a method, which is highly efficient to prime stem or progenitor cells to differentiation using non-attachment matrices and differentiation supporting component. The cells produced therefrom may be used to treat a variety of neurodegenerative disorders.Type: GrantFiled: February 17, 2010Date of Patent: January 6, 2015Assignee: Cellin Technologies OUEInventors: Kaia Palm, Toomas Neuman
-
Patent number: 8841089Abstract: The present invention relates to polynucleotides comprising a first nucleic acid sequence for a chromatin element, which is capable of enhancing expression, and at least one second nucleic acid sequence comprising a curved origin motif. Furthermore, the invention relates to a host cell, a non-human transgenic organism, a vector and a kit comprising the aforementioned polynucleotide. Moreover, the invention relates to methods for expressing a polynucleotide of interest.Type: GrantFiled: March 28, 2008Date of Patent: September 23, 2014Assignee: Hochschule MannheimInventors: Manfred Frey, Heiko Flammann, Mathias Hafner
-
Patent number: 8728815Abstract: This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents.Type: GrantFiled: June 5, 2012Date of Patent: May 20, 2014Assignee: University of Southern CaliforniaInventor: Valter Longo
-
Patent number: 8679838Abstract: It is intended to provide a serum which contains a large amount of growth factors capable of efficiently promoting the growth of stem cells. A human serum for cell culture which shows a residual ratio of platelets remaining within 20 minutes after blood collection in relation to the whole amount of the platelets is 0% to 20%, and a release ratio of cell growth factors is 20% to 100%.Type: GrantFiled: February 12, 2010Date of Patent: March 25, 2014Assignee: JMS Co., Ltd.Inventors: Koji Suzuki, Seishin Tanaka
-
Patent number: 8623650Abstract: The present invention provides compositions and methods for the culture and maintenance of pluripotent stem cells. More particularly, the present invention provides for compositions and methods for culturing, maintaining, growing and stabilizing primate pluripotent stem cells in a feeder-free defined media further comprising human serum, or a soluble attachment component of the human serum, for promoting cell attachment.Type: GrantFiled: October 19, 2007Date of Patent: January 7, 2014Assignee: Viacyte, Inc.Inventors: Allan J. Robins, Thomas C. Schulz
-
Patent number: 8617887Abstract: The present invention is generally in the field of neurological diseases and disorders, particular in the field of neurodegenerative diseases in which the myelin cover of nerves is lost. IL6R/IL6 chimera is used to promote the formation of oligodendrocytes from embryonic stem cells for treatment of neurodegenerative diseases or posttraumatic nerve damage.Type: GrantFiled: June 13, 2004Date of Patent: December 31, 2013Assignee: Yeda Research and Development Co. LtdInventors: Michel Revel, Peter Lonai, Rozemari Stirbu Lonai
-
Publication number: 20130130382Abstract: To provide an autoserum-containing bone marrow cell culture system, whereby bone marrow cells, which are collected from a subject without using an anticoagulant, are subjected to an anticoagulation treatment using a medium in a liquid-tight state, cultured and then further cultured using the serum of said subject which is prepared in a liquid-tight state; an autoserum-containing bone marrow cell culture method; and a method for producing a medicinal composition which comprises, as the active ingredient, autoserum-containing cultured bone marrow cells. [Solution] An autoserum-containing bone marrow cell culture system for culturing bone marrow cells, which are collected from a subject without using an anticoagulant, using the serum of said subject, said system comprising a bone marrow cell suspension-storing device, a collected blood-storing device, an autoserum-acquiring device, and a bone marrow cell-culturing device.Type: ApplicationFiled: August 3, 2011Publication date: May 23, 2013Applicant: SAPPORO MEDICAL UNIVERSITYInventors: Osamu Honmou, Yoshihiro Yoshikawa, Naomi Morikawa
-
Patent number: 8426200Abstract: The present invention relates to compositions and methods for culturing stem cells, such that neuronal differentiation can be achieved.Type: GrantFiled: July 2, 2004Date of Patent: April 23, 2013Assignee: Regents of the University of MinnesotaInventors: Catherine Verfaillie, Yuehua Jiang
-
Patent number: 8420394Abstract: Disclosed are methods for expanding stem cells that use a unique combination of environmental factors and cell culture conditions to produce stem cells having enhanced proliferation and differentiation characteristics. Also disclosed are methods for enhancing the engraftment and/or migratory potential of stem cells for therapeutic uses. Stem cells having unique proliferation, differentiation, migratory and engraftment characteristics are also disclosed.Type: GrantFiled: March 24, 2009Date of Patent: April 16, 2013Inventors: Chih-Min Lin, Alex Wharazi
-
Patent number: 8257947Abstract: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible three-dimensional surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.Type: GrantFiled: January 30, 2009Date of Patent: September 4, 2012Inventors: Gail K. Naughton, Frank Ziegler, Mark Baumgartner, Kyle Nickey
-
Patent number: 8211700Abstract: This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents.Type: GrantFiled: March 28, 2008Date of Patent: July 3, 2012Assignee: University of Southern CaliforniaInventor: Valter Longo
-
Patent number: 7993917Abstract: Methods for the diagnosis of visceral, cutaneous and canine leishmaniasis in a subject suspected of being infected with the parasitic protozoa Leishmania is disclosed. Disclosed are antibody-capture enzyme-linked immunosorbent assays (ELISAs) for the detection of antibodies to Leishmania parasite soluble antigens and antigen-capture ELISAs for the detection of Leishmania parasite soluble antigens in host samples. Also disclosed are immunodiagnostic kits for the detection of Leishmania parasite circulating antigens or IgM and IgG antibodies in a sample from subject having visceral, cutaneous or canine leishmaniasis. In these methods and kits, detection may be done photometrically or visually. The methods and kits also allow the visualization of Leishmania amastigotes or promastigotes in a sample.Type: GrantFiled: August 20, 2009Date of Patent: August 9, 2011Assignee: The United States of America as represented by the Secretary of the ArmyInventor: Samuel K. Martin
-
Patent number: 7977063Abstract: The present invention concerns a method for determining an allergic response by determining the extent of degranulation of human IgE sensitized cells upon activation by allergens in food products.Type: GrantFiled: March 16, 2005Date of Patent: July 12, 2011Assignee: N.V. NutriciaInventors: Virginie Sophie Christelle Tregoat, Johan Garssen
-
Patent number: 7709258Abstract: The present invention relates generally to high-throughput assay methods that determine the proliferative status of hematopoietic stem and progenitor cells. The present invention further relates to high-throughput assays for screening compounds that modulate the growth of hematopoietic stem and progenitor cells and for identifying subpopulations thereof that are suitable for transplantation. The assay of the present invention is particularly useful for quality control and monitoring of the growth potential in the stem cell transplant setting and would provide improved control over the reconstitution phase of transplanted cells.Type: GrantFiled: March 17, 2008Date of Patent: May 4, 2010Assignee: HemoGenix, Inc.Inventor: Ivan N. Rich
-
Publication number: 20100105108Abstract: A method of making a vaccine using animal derived component free (ADCF) cell culture technology, including the steps of attaching ADCF-adapted cells to a microcarrier including an attachment mechanism for attaching filipodia of the cells, the microcarrier being in a culture, growing the cells in ADCF maintenance media, infecting the cells with vaccine media, producing virus within the cells, and harvesting the virus. A vaccine produced by the above method in a pharmaceutically acceptable carrier. A vaccine production structure of ADCF-adapted cells removably attached to microcarrier beads including an attachment mechanism for attaching filipodia of the cells.Type: ApplicationFiled: December 18, 2009Publication date: April 29, 2010Applicant: SOLOHILL ENGINEERING, INC.Inventors: Bonnie L. Wallace, William J. Hillegas
-
Patent number: 7700352Abstract: The invention aims to proliferate or establish undifferentiated pluripotent stem cells that retain their differentiation potency by culturing pluripotent stem cells in a medium free of a feeder cell, or a serum. The aim is attained by using a culture medium for pluripotent stem cells comprising the known ingredients, which is supplemented with an inhibitor of an adenylate cyclase activity.Type: GrantFiled: October 31, 2003Date of Patent: April 20, 2010Assignee: RikenInventors: Hitoshi Niwa, Kazuya Ogawa
-
Patent number: 7700354Abstract: The present invention relates generally to high-throughput assay methods that determine the proliferative status of hematopoietic stem and progenitor cells. The present invention further relates to high-throughput assays for screening compounds that modulate the growth of hematopoietic stem and progenitor cells and for identifying subpopulations thereof that are suitable for transplantation. The assay of the present invention is particularly useful for quality control and monitoring of the growth potential in the stem cell transplant setting and would provide improved control over the reconstitution phase of transplanted cells.Type: GrantFiled: March 17, 2008Date of Patent: April 20, 2010Assignee: HemoGenix, Inc.Inventor: Ivan N. Rich
-
Patent number: 7666615Abstract: The present invention relates generally to assays, methods, and kits that provide reagent mixes and instructions for determining the proliferative status of isolated target cell populations. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells.Type: GrantFiled: November 17, 2006Date of Patent: February 23, 2010Assignee: HemoGenix, Inc.Inventor: Ivan N. Rich
-
Patent number: 7666673Abstract: The present invention provides a method of growing spermatogonial stem cells of mammals and the like in vitro, which is characterized in that glial cell-derived neurotrophic factor (GDNF) or an equivalent thereto, and leukemia inhibitory factor (LIF) are contained in a medium (culture broth) for culturing spermatogonial stem cells. According to the method of the present invention, spermatogonial stem cells can be grown in vitro to the extent that enables use thereof for developmental engineering.Type: GrantFiled: March 31, 2004Date of Patent: February 23, 2010Assignee: Kyoto UniversityInventors: Takashi Shinohara, Mito Shinohara
-
Patent number: 7651847Abstract: The present invention provides methods for identifying oligosaccharides specific to cancer and methods for determining a strain of cancer in an individual. The present invention also provides methods for diagnosing cancer or a stage of cancer in an individual by detecting the presence or absence of specific cancer markers and methods for treating cancer by administering antibodies directed to such markers. In addition, the present invention provides cancer markers comprising O-linked oligosaccharides and kits for diagnosing or treating cancer.Type: GrantFiled: June 20, 2005Date of Patent: January 26, 2010Assignee: The Regents of the University of CaliforniaInventors: Carlito B. Lebrilla, Hyun Joo An, Kit S. Lam, Suzanne Miyamoto
-
Patent number: 7645609Abstract: The invention provides media and methods for culturing mammalian cells whereby the sialylation of a protein produced by the cells is increased. The medium can contain N-acetylmannosamine and, optionally, galactose. The medium may also comprise fructose and mannose. Alternatively, the medium can contain galactose and fructose and, optionally, can also comprise mannose and/or N-acetylmannosamine. The methods can be practiced along with other methods for culturing cells so as to increase the quantity or quality of a protein produced by the cells, including culturing the cells at a temperature below 37° C.Type: GrantFiled: July 15, 2003Date of Patent: January 12, 2010Assignee: Immunex CorporationInventor: Brian D. Follstad
-
Publication number: 20090246182Abstract: The invention concerns a method for culturing cells derived from the adipose tissue and in particular the stromal vascular fraction (SVF) to induce formation of cardiomyocytes, the use of the cells obtained by said culture method to reconstitute an ischemized cardiac zone, in particular following an infarction, as well as a pharmaceutical composition containing said cells. The method for obtaining cardiac cells comprises at least the following steps: a) selecting cardiomyogenic cells from the stromal vascular fraction (SVF); b) culturing the cells selected at step a) in a liquid medium optimized for expanding ex vivo the cardiomyogenic cells; c) maintaining and expanding said cells by successive passes in the liquid medium; and d) obtaining cardiac cells.Type: ApplicationFiled: January 26, 2007Publication date: October 1, 2009Inventors: Louis Casteilla, Valerie Planat-Benard, Luc Penicaud, Carine Chanut
-
Publication number: 20090093056Abstract: Methods of generating and expanding proliferative, multipotent connective tissue progenitor cells from adult stem cells are provided. Also provided are methods of generating functional tendon grafts in vitro and bone, cartilage and connective tissues in vivo using the isolated cell preparation of connective tissue progenitor cells.Type: ApplicationFiled: January 11, 2007Publication date: April 9, 2009Applicant: Technion Research & Development Foundation Ltd.Inventors: Joseph Itskovitz-Eldor, Shahar Cohen
-
Patent number: 7514261Abstract: The invention provides methods of treating and preventing loss of tissue vascularization that can occur, for example, upon aging.Type: GrantFiled: August 8, 2002Date of Patent: April 7, 2009Assignee: Cornell Research Foundation, Inc.Inventors: Jay M. Edelberg, Shahin Rafii, Mun K. Hong
-
Patent number: 7501231Abstract: The invention can be summarized as follows. The present invention provides cell culture compositions and cell cryopreservation compositions for culturing and cryopreserving enteric system (ENS) neurons and central nervous system (CNS) neurons. The present invention also provides a method of culturing and cryopreserving ENS and CNS cells. The compositions of the present invention comprise nutrient medium, serum, glutamine, glucose an antibiotic and one or more of the following components: one or more mitotic inhibitors, one or more antioxidants, and a cryopreservative.Type: GrantFiled: March 25, 2002Date of Patent: March 10, 2009Assignee: University of OttawaInventors: William Staines, Anthony Krantis
-
Publication number: 20080286243Abstract: The present invention relates to a method for isolating hair follicle stem cells and a composition for inducing hair growth. More specifically, relates to a method for isolating hair follicle stem cells showing a positive immunological response to CD34, by chemically degrading hair follicle-containing scalp tissue and then culturing the degraded tissue in a serum-containing medium and a serum-free medium, as well as a composition for inducing hair growth, which contains, as an active ingredient, CD34-positive hair follicle stem cells isolated by the method. The hair follicle-derived stem cells, which are obtained according to the disclosed method, are classified as autologous adult stem cells, have self-renewal capability, the ability to differentiate into adult hair follicle cells and the ability to induce hair growth, and can be used as a novel cell therapeutic agent against hair loss.Type: ApplicationFiled: July 4, 2007Publication date: November 20, 2008Applicants: SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION, RNL BIO CO., LTD.Inventors: Kyung Sun Kang, Jeong Chan Ra
-
Patent number: 7452721Abstract: Methods for the diagnosis of visceral, cutaneous and canine leishmaniasis in a subject suspected of being infected with the parasitic protozoa Leishmania is disclosed. Disclosed are antibody-capture enzyme-linked immunosorbent assays (ELISAs) for the detection of antibodies to Leishmania parasite soluble antigens and antigen-capture ELISAs for the detection of Leishmania parasite soluble antigens in host samples. Also disclosed are immunodiagnostic kits for the detection of Leishmania parasite circulating antigens or IgM and IgG antibodies in a sample from subject having visceral, cutaneous or canine leishmaniasis. In these methods and kits, detection may be done photometrically or visually. The methods and kits also allow the visualization of Leishmania amastigotes or promastigotes in a sample.Type: GrantFiled: November 18, 2004Date of Patent: November 18, 2008Assignee: The United States of America as represented by the Secretary of the ArmyInventor: Samuel K. Martin
-
Patent number: 7410787Abstract: The invention relates to a method for in vitro seriological diagnosis of Whipple's disease, whereby the bacteria responsible for the disease are isolated and established in a culture and brought into contact with the serum or biological fluid of an infected patient. The invention also relates to useful oligonucelotides with a probe and a primer for amplifying, sequencing and detecting the gene rpoB of the bacteria, Tropheryma whippelii.Type: GrantFiled: March 24, 2000Date of Patent: August 12, 2008Assignee: Protisvalor MediterraneeInventors: Didier Raoult, Bernard La Scola, Marie-Laure Birg, Florence Fenollar
-
Patent number: 7354729Abstract: The present invention relates generally to high-throughput assay methods that determine the proliferative status of hematopoietic stem and progenitor cells. The present invention further relates to high-throughput assays for screening compounds that modulate the growth of hematopoietic stem and progenitor cells and for identifying subpopulations thereof that are suitable for transplantation. The assay of the present invention is particularly useful for quality control and monitoring of the growth potential in the stem cell transplant setting and would provide improved control over the reconstitution phase of transplanted cells.Type: GrantFiled: January 29, 2002Date of Patent: April 8, 2008Assignee: HemoGenix, Inc.Inventor: Ivan N. Rich
-
Patent number: 6989271Abstract: There is provided a method of inducing bone marrow stromal cells to differentiate into bone marrow stromal cell-derived Schwann cells in vitro, comprising the steps of: collecting bone marrow stromal cells from bone marrow and culturing the cells in a standard essential culture medium supplemented with a serum; adding a reducing agent to the culture medium and further culturing the cells; adding a differentiation inducing agent to the culture medium and further culturing the cells; and adding a cyclic AMP-augmenting agent or a cyclic AMP analogue and/or a glial cell differentiation and survival stimulating factor to the culture medium, and further culturing the cells to obtain the bone marrow stromal cell-derived Schwann cells. There are also provided bone marrow stromal cell-derived Schwann cells obtained thereby and a pharmaceutical composition for neural regeneration that comprises them.Type: GrantFiled: June 21, 2002Date of Patent: January 24, 2006Assignee: Sanbio, Inc.Inventors: Mari Dezawa, Hajime Sawada, Masahiko Takano
-
Patent number: 6960473Abstract: We describe a new two-step culture method for mass production in vitro of erythroid cells from either CD34+ (105 cells/mL) or light-density (106 cells/mL) cells purified from the blood of normal donors and thalassemic patients. The method includes (i) culture of the cells in the presence of dexamethasone and estradiol (10?6 M each) and (ii) the growth factors SCF (50 ng/mL), IL-3 (1 ng/mL), and EPO (1 U/mL). In their proliferative phase, these cultures generated about 1-2×107 erythroblasts for each milliliter of blood collected from normal donors or thalassemic patients. They were composed mostly (90%) of CD45low/glycophorin (GPA)neg/CD71low cells at day 7, 50-60% of which became CD45neg/GPA+/CD71high by days 15-20. However, when cells from days 7 to 12 of the proliferative phase were transferred in differentiation medium containing EPO and insulin, they progressed to mature erythroblasts (>90% benzidinepos and CD45neg/GPA+/CD71medium) in 4 days.Type: GrantFiled: February 26, 2004Date of Patent: November 1, 2005Assignee: Istituto Superiore di SanitaInventors: Giovanni Migliaccio, Anna Rita Franco
-
Patent number: 6838089Abstract: The present invention concerns polymer particle vaccine delivery systems in which a water insoluble protein antigen, e.g. a lipidated HpaA protein, is incorporated with particles comprising a polymer matrix. The present invention also concerns a method for incorporating such a water insoluble protein antigen with a polymer matrix in order to produce a polymer particle vaccine delivery system. In addition, the invention also provides a vaccine composition comprising the polymer particle delivery system. The vaccine can be used to treat and/or reduce the risk of for example Helicobacter infection.Type: GrantFiled: April 9, 1999Date of Patent: January 4, 2005Assignee: AstraZeneca ABInventors: Hans Carlsson, Anette Larsson, Erik Söderlind
-
Patent number: 6610535Abstract: The present invention relates to a substantially pure population of viable pancreatic progenitor cells, and methods for isolating such cells. The present invention further concerns certain therapeutic uses for such progenitor cells, and their progeny.Type: GrantFiled: November 28, 2000Date of Patent: August 26, 2003Assignee: ES Cell International Pte Ltd.Inventors: Kuanghui Lu, Kevin Pang, Lee Rubin
-
Patent number: 6599740Abstract: A process of using a fish plasma component as a nutrient medium component for tissue culture includes obtaining blood from a fish, separating plasma from the blood, and extracting one or more specific components of the plasma. The tissue is cultured using the extracted plasma components, and none of any remainder of the plasma, in a nutrient medium. The tissue cultured using the extracted plasma component is other than fish tissue, such as mammalian tissue or insect tissue.Type: GrantFiled: July 18, 2001Date of Patent: July 29, 2003Assignee: Sea Run Holdings, Inc.Inventors: Evelyn A. Sawyer, Paul A. Janmey, Lisa A. Flanagan
-
Patent number: 6558949Abstract: This invention relates to media for culturing human cells that the proliferation speed of human cells is increased and the cell expression type is stably manifested, and to a method for culturing human cells using the same. This invention is characterized in that the media used for culturing human cells comprises human serum.Type: GrantFiled: December 13, 2000Date of Patent: May 6, 2003Inventors: Byoung-Hyun Min, So Ra Park
-
Publication number: 20030008394Abstract: A method for culturing Langerhans islets to obtain an amount sufficient for transplant and autotransplant is disclosed. The islets are cultured in a culture serum (rat/human) medium which is supplemented with radical scavengers, growth factors, a matrix material, nerve growth factor, cell migrating/scattering factors and anti-integrin &bgr;1 antibody at proper the time during the culturing process The medium is supplemented with radical scavengers and growth factors for the first time and then further supplemented with matrix material, radical scavengers, nerve growth factor and the growth factors around 12-24 hours after culturing. Thereafter, the medium is supplemented with growth factors, cell migrating/scattering factors and anti-integrin &bgr;1 antibody at 4-5 days into the culturing process.Type: ApplicationFiled: July 19, 2002Publication date: January 9, 2003Inventor: Tai-Wook Yoon
-
Patent number: 6500668Abstract: A culture medium for avian embryonic cells and an avian cell culture medium is disclosed. The culture medium is characterized in that it has elements complementary to avian embryonic cells. The complementary elements are cytokines, fibroblast growth factors, insulin-like growth factors or stem cell growth factors. The medium is substantially free of active retinoic acid. A method for culturing avian embryonic cells, and the resulting products, are also disclosed.Type: GrantFiled: September 1, 1999Date of Patent: December 31, 2002Inventors: Jacques Samarut, Bertrand Pain
-
Publication number: 20020187551Abstract: A method for culturing Langerhans islets to obtain an amount sufficient for transplant and autotransplant is disclosed The islets are cultured in a culture serum (rat/human) medium which is supplemented with radical scavengers, growth factors, a matrix material, nerve growth factor, cell migrating/scattering factors and anti-integrin &bgr;1 antibody at proper the time during the culturing process. The medium is supplemented with radical scavengers and growth factors for the first time and then further supplemented with matrix material, radical scavengers, nerve growth factor and the growth factors around 12-24 hours after culturing. Thereafter, the medium is supplemented with growth factors, cell migrating/scattering factors and anti-integrin &bgr;1 antibody at 4-5 days into the culturing process. The culturing process is conducted for an extended period of time, so that any latent red blood cells are eliminated from the islet culture.Type: ApplicationFiled: July 8, 2002Publication date: December 12, 2002Inventor: Tai-Wook Yoon
-
Publication number: 20020177228Abstract: A method for preparing a preparation of mammalian pancreatic endocrine cells comprising the steps: dissociating intact pancreatic tissue into a cell suspension comprising single cells and cell aggregates; enriching said cell suspension with regard to the content in endocrine cells by separating single cells and cellular aggregates with size <100 &mgr;m; and removing contaminating non-endocrine cells by density centrifugation.Type: ApplicationFiled: April 12, 2001Publication date: November 28, 2002Applicant: Beta-Cell N.V.Inventor: Daniel Pipeleers
-
Patent number: 6436701Abstract: A method of selecting and growing pluripotential embryonic stem cells isolated from an ungulate species blastocysts of embryos that develop by way of an embryonic disc is disclosed. The method comprises growing blastocysts in tissue culture growth medium which includes both heat-inactivated new born calf serum and heat-inactivated fetal calf serum; disaggregating the blastocysts either after spontaneous hatching or after mechanical removal of the zone pellucida; growing stem cell colonies from the disaggregated cells in issue culture growth medium; selecting stem cell colonies by morphological characteristics; and growing the selected stem cells in tissue culture growth medium. The cells are round cells, tightly packed with large nuclei in relation to cytoplasm, and fairly prominent nucleoli. They grow in tightly adherent coloedes and as the colonies get larger the cells tend to flatten out in the center of the colony.Type: GrantFiled: April 23, 1991Date of Patent: August 20, 2002Assignee: Babraham InstituteInventors: Martin John Evans, Robert Michael Moor, Elena Notaranni
-
Publication number: 20020076814Abstract: A process of using a fish plasma component as a nutrient medium component for tissue culture includes obtaining blood from a fish, separating plasma from the blood, and extracting one or more specific components of the plasma. The tissue is cultured using the extracted plasma components, and none of any remainder of the plasma, in a nutrient medium. The tissue cultured using the extracted plasma component is other than fish tissue, such as mammalian tissue or insect tissue.Type: ApplicationFiled: July 18, 2001Publication date: June 20, 2002Inventors: Evelyn A. Sawyer, Paul A. Janmey, Lisa A. Flanagan
-
Publication number: 20020076813Abstract: Compositions for stabilizing polypeptides or antigens are described. These compositions are useful for stabilizing polypeptides or antigens stored in aqueous formulations. Such formulations can be used for various analytical or other methods.Type: ApplicationFiled: December 14, 2000Publication date: June 20, 2002Inventors: Jeffrey W. Steaffens, Laura Panzarella
-
Patent number: 6383805Abstract: A method and a medium for culturing epithelial cells of both normal and malignant origin is provided. The method entails physically disaggregating tissue samples, placing the resulting fragments onto a surface comprised of basement membrane matrix components, and culturing the tissue in a medium containing preselected fetal and newborn calf sera and rat sera. Both primary explant cell cultures and cell lines, which are long-lived and particularly suitable for further study, are produced. The cultured primary explant cells undergo differentiation to form complex structures resembling those seen in vivo.Type: GrantFiled: April 11, 2000Date of Patent: May 7, 2002Assignee: University of PittsburghInventor: Jean J. Latimer
-
Patent number: 6261805Abstract: The present disclosure utilizes a novel approach to protein preparation in the baculovirus expression vector system (BEVS). Specifically, the present invention analyzes the effects of microgravity/low shear on complex glycosylation of proteins prepared via BEVS, including the addition of terminal sialic acid residues to N-linked oligosaccharides.Type: GrantFiled: July 15, 1999Date of Patent: July 17, 2001Assignee: Boyce Thompson Institute for Plant Research, Inc.Inventor: H. Alan Wood
-
Patent number: 6204056Abstract: A patient replica is created from layered culture medium where solid culture medium is formed so that a discontinuity exists, for example, between layers of culture medium or between culture medium and the container holding the medium. An injection port is provided in registration with the discontinuity so that a sample of patient blood can be infused into the discontinuity to form a thin layer of blood in contact with a surface of culture medium. The thin layer of blood obviates the requirement for any anticoagulant allowing blood-borne pathogens to be readily cultured without using broth. Further antibiotics or other drug samples may be placed on an exposed surface of the culture medium above the blood layer so that the antibiotic can diffuse through the culture medium and reveal the sensitivities of the cultured pathogens.Type: GrantFiled: September 3, 1999Date of Patent: March 20, 2001Inventors: Allen C. Barnes, Janice S. Barnes